Schalper et al. published an analysis of baseline serum IL-8 levels in samples from 1344 patients treated with nivolumab monotherapy or the combination of nivolumab plus ipilimumab in several phase III clinical trials: CheckMate 067 in melanoma patients; CheckMate 017 and CheckMate 057 in advanced NSCLC patients and CheckMate 025 in renal cells cancer patients. The gene discussed is CXCL8; the disease is non-small cell lung carcinoma.